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Ten samples containing various amounts of methicillin-resistant Staphylococcus aureus (MRSA), methicillin-
susceptible S. aureus, methicillin-resistant Staphylococcus epidermidis (MRSE), and combinations thereof were
distributed to 51 laboratories for molecular diagnostics testing. Samples containing 102 to 103 MRSA cells were
frequently reported to be negative. MRSE samples were scored as negative by all commercial tests but by only
two out of three in-house tests.
Methicillin-resistant Staphylococcus aureus (MRSA) re-
quires timely detection in order to prevent infection and nos-
ocomial transmission (1, 4). Classical microbiologists routinely
use culture-based enrichment assays as the basis for detection
and subsequent identification. The inclusion of an elevated salt
concentration and specific antibiotics in the growth medium
allows for highly specific detection (8). However, culture re-
quires prolonged incubation periods, and in general, confirma-
tory assays are required upon positive culture. Molecular as-
says may offer benefits over more traditional culture-based
assays, such as reduced time to identification and better spec-
ificity and sensitivity. The commercial diagnostics industry has
introduced a range of molecular assays in recent years. How-
ever, there is little information available on their performance,
and some studies suggest that they may suffer from reduced
sensitivity as a result of sample inhibition (3). Specificity may
also be an issue as the presence of methicillin-resistant coag-
ulase-negative staphylococci, including methicillin-resistant
Staphylococcus epidermidis (MRSE), may result in false-posi-
tive results. Given the number of commercially available test
systems, the clinical impact of MRSA, and the need for timely
diagnostics, a multicenter external quality assessment (EQA)
study on the efficiency and efficacy of molecular testing for
MRSA was initiated by Quality Control for Molecular Diag-
nostics (QCMD) (www.qcmd.org).
The QCMD MRSA EQA panel samples were distributed in
October 2006 to 51 participating laboratories from 11 coun-
tries, along with detailed instructions on how to process the
panel samples. Participants were given 6 weeks to report their
results back to the QCMD Neutral Office by using an online
data collection system.
The QCMD 2006 MRSA panel consisted of five samples
containing various amounts of MRSA, three samples contain-
ing various amounts of staphylococci other than S. aureus, and
one sample containing Escherichia coli (Table 1). The contents
of the samples were quantified on the basis of culture and
molecular testing results. The IDI-MRSA test (Becton Dick-
inson) was employed in combination with the Sigma plant
DNA isolation kit according to the manufacturers’ instruc-
tions.
Out of the 51 participants, 46 (90%) responded. Nonrespon-
dents indicated technical problems (n  2) or “test under
development” (n  2) as the reason for not returning results.
Overall, 58 data sets were returned, 55 of which included
qualitative data only; three labs reported both qualitative and
quantitative data. All participants received the expected results
following the close of the program. Subsequently, the QCMD
Neutral Office analyzed the data, which was released to par-
ticipants in the form of a detailed EQA final report.
Most of the real-time data were generated with the Roche
LightCycler system (n  14), Roche LightCycler 2.0 (n  6),
and the Corbett Research Rotor-Gene 3000 (n  5) and
Applied Biosystems systems (the ABI 7500 real-time PCR
system [n  6], the ABI PRISM 7000 sequence detection system
[n  5], and the ABI PRISM 7900 sequence detection system
[n  1]). Two Bio-Rad machines were included, and the Ce-
pheid Smart Cycler II system, Roche LightCycler 480, and the
Stratagene MxP3000 real-time system each provided a single
data set. For the in-house conventional PCRs, the Eppendorf
MasterCycler, the MWG AG Biotech Primus 96, and the Per-
kin-Elmer 9600 were used. The diversity of the equipment
covers the spectrum commercially available systems quite well.
QCMD used a simple scoring system for qualitative EQA
data, which was as follows: 2 points for a correct result and 0
points for all other results (including “not determined” and
“equivocal”). The results obtained are summarized in Table 2.
Results for the panel sample with the highest number of
MRSA cells (MRSA06-08) were reported correctly in 97% of
the data sets. This finding indicates that the usage of molecular
tests to follow up positive cultures is reliable: all the tests can
be used for culture confirmation. However, the samples con-
taining smaller amounts of MRSA (MRSA06-09 and
MRSA06-06) had levels that were below the limit of detection
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of most participants’ assays. Only 12 and 52% of the data sets
included correct results for these samples. MRSE sample
MRSA06-07 was correctly reported as negative for MRSA by
all commercial PCR tests but incorrectly reported as positive in
33% (1 of 3) of data sets generated with conventional in-house
assays and 21% (9 of 43) of data sets generated using real-time
in-house PCR. The methicillin-susceptible S. aureus (MSSA)-
containing sample MRSA06-10 was scored incorrectly by both
commercial and in-house tests (17% of conventional PCR tests
and 9% of real-time PCR tests), indicating moderate specific-
ity. These levels of false positives underscore the need for
improved specificity of these MRSA tests. Even the E. coli
specimen could not be adequately tested (results were inde-
terminate in 7% [4 of 58] of data sets). Table 3 summarizes the
performance scores for the various PCR platforms. The per-
formance of the commercial conventional PCRs and the in-
house real-time PCRs can be considered satisfactory. How-
ever, only three participants attained the maximum score of 20.
Quality control of molecular diagnostics tools is important in
order to maintain high-quality clinical care in medical institu-
tions. Multicenter studies on the sensitivity and specificity of
several bacterial and viral DNA tests have been performed in
the past, and the outcomes of such studies have provided
important information on performance (2, 5, 6, 7). Here we
report on an EQA study of one of the most important noso-
comial bacterial pathogens, MRSA. In conclusion, the molec-
ular identification of MRSA by using samples with high CFU
counts is reliable and can be implemented in the laboratory
setting with confidence. Essentially, all testing formats perform
equally well. However, for direct molecular diagnostics, we
have to conclude that the present array of tests do not meet the
clinical quality criteria. The sensitivity of many tests is (too)
low, and the specificity needs to be improved. The reasons for
poor assay sensitivity may be grounded in the common practice
of preenriching samples by culture before confirmation by mo-
lecular assays. Preenrichment may lead to concentrations of
MRSA in excess of 1010 CFU/ml, which is greater than the
concentrations of MRSA likely to be encountered in an un-
modified patient sample (and those in this EQA panel). Some
assays may have been designed specifically for this higher tar-
get concentration range, leading to poor levels of sensitivity.
The preenrichment approach also reduces one of the key im-
provements offered by molecular assays, which is more rapid
diagnosis. The sensitivity of molecular assays for the detection
of MRSA will improve only if the molecular diagnostics com-
munity moves away from preenrichment and tests directly from
TABLE 1. Panel composition and results of independent testinga
Sample Sample content(s) Target sample concn(CFU/ml)
Indicated in-process testing result Sample
statusQualitative CT value
MRSA06-01 MRSA 103  20.0 
MRSA06-02 MSSA and MRSE 103 and 105  45 
MRSA06-03 E. coli 109  45 
MRSA06-04 MRSA 106  18.0 
MRSA06-05 MSSA and MRSE 103 and 104  45 
MRSA06-06 MRSA 103  20.0 
MRSA06-07 MRSE 109  45 
MRSA06-08 MRSA 109  15.0 
MRSA06-09 MRSA 102  25.0 
MRSA06-10 MSSA 109  45 
a All samples were provided in Mueller-Hinton broth. The MRSA strain was S. aureus N315, the MSSA strain was ATCC 29213, and the MRSE strain was 260. E.
coli strain ATCC 35218 was used. For in-process testing, the IDI-MRSA test (Becton Dickinson) was employed with the Sigma plant DNA isolation kit as the processing
unit for the extraction of DNA from the samples. The cycle threshold (CT) value identifies the cutoff value for a positive score: when the CT was 45, a sample could
be considered negative. In the case of a CT of 45, the sample was positive, and the samples with highest titers scored the lowest CT values.
TABLE 2. Technology types and numbers of correct qualitative results per panel sample
Sample Sample content(s) (concn, CFU/ml)
Total quantity
of correct
results (n  58)
Quantity of correct results from indicated PCR type
Conventional
commercial







No. % No. % No. % No. %
MRSA06-01 MRSA (103) 30 52 6 50 1 33 23 54
MRSA06-02 MSSA and MRSE (103 and 105) 55 95 12 100 3 100 40 93
MRSA06-03 E. coli (109) 54 93 9 75 3 100 42 98
MRSA06-04 MRSA (106) 48 83 12 100 2 67 34 79
MRSA06-05 MSSA and MRSE (103 and 104) 56 97 12 100 3 100 41 95
MRSA06-06 MRSA (103) 30 52 4 33 1 33 25 58
MRSA06-07 MRSE (109) 48 83 12 100 2 67 34 79
MRSA06-08 MRSA (109) 56 97 12 100 3 100 41 95
MRSA06-09 MRSA (102) 7 12 2 17 0 0 5 12
MRSA06-10 MSSA (109) 51 88 10 83 2 67 39 91
a The commercial tests were the Hain GenoQuick MRSA (n  2), the Hain GenoType MRSA direct (n  1), the Hain GenoID MRSA (n  1), the Hyplex
Staphyloresist (n  1), and the Becton Dickinson IDI-MRSA (n  7) tests.











the clinical sample. Performance would also be improved by
the provision of proper quality control materials and interna-
tional standards for MRSA testing.
Although the stage has been set for direct clinical detection
of MRSA, our data here indicate that the present testing sys-
tems are insufficient. And clinical practice may even be worse:
here we used clean samples, and in the case of samples such as
urine, blood, and sputa, inhibitory compounds within these
samples may deteriorate the test performance. These data
clearly support the need for improvements in the molecular
detection of MRSA.
The QCMD program is organized in collaboration with the Euro-
pean Society for Clinical Virology and the European Society for Clin-
ical Microbiology and Infectious Diseases. Panels were produced in
the Department of Medical Microbiology and Infectious Diseases of
Erasmus MC, Rotterdam, The Netherlands. Nothing in this report
may be reproduced without permission of the QCMD Executive
Office.
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TABLE 3. Qualitative performance scores per technology typea









No. with indicated score
25% 75% 6 8 10 12 14 16 18 20
Conventional
Commercial 12 15.17 1.99 14 14 16.5 0 0 0 1 6 2 3 0
In-house 3 13.33 2.31 12 12 14 0 0 0 2 0 1 0 0
Real time, in-house 43 15.07 2.84 16 14 18 0 1 2 10 17 13 12 3
a For a correct result, 2 points were scored; 0 points were scored for any other result. A maximum of 20 points could be obtained. The 25% quartile may be taken
to be the median of the lower half of the scores provided for each group, and the 75% quartile corresponds to the median of the upper half of the scores.
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